Evaluate for Pharma & Biotech

Text with Title

Evaluate gives you the understanding and time you need to drive better decisions. 

Our clients include the Top 25 global pharma companies, as well as small to mid-sized pharma and biotechs. Evaluate is relied upon by their commercial teams from Business Development & Licensing to Corporate Strategy & Planning, Competitive Intelligence, and Market Analytics. 

With solutions suitable for asset screening, market analysis, competitive intelligence and portfolio strategy, Evaluate Pharma reduces the cost, time and risk associated with making strategic decisions.


Business development & licensing

Business Development & Licensing

Predict future performance with confidence
  • Benchmark deals to improve value and structure
  • Screen for potential assets and identify candidates for in-licensing and acquisition fitting your specific area
  • Identify risk and evaluate potential assets earlier in the screening process with a single view of the risk and return of the R&D landscape
  • Build detailed product profiles, with key developments, licensing, regulatory and expected future events
Business development & licensing
Market Analytics & Competitive Intelligence

Market Analytics & Competitive Intelligence

Provide trusted competitive intelligence
  • Build market sizing models and identify the products that are forecast to grow
  • Evaluate competing assets using a single view of the risk and return of the R&D landscape
  • Benchmark internal forecasts against the financial market's view for your products and key competitors, understand how forecasts have changed over time
  • Quickly build competitive landscapes for your portfolio by EphMRA code, therapy area, indication and mechanism of action
Corporate Strategy & Planning

Corporate Strategy & Planning

Drive business growth and profitability
  • Evaluate developmental assets in a target company using a single view of the risk and return of the R&D landscape
  • Benchmark your performance in sales, profits and expenditure against your peers
  • Build your information base, and a customised industry view, from a single, standardised source
  • Track changes in forecasts for products and R&D pipeline to understand how the market views your products
Knowledge Management

Knowledge Management

Deliver transparent insights faster
  • Refresh models and spreadsheets instantly with the latest data
  • Quickly and easily gather a wide range of market data from a single, standardised platform
  • Deliver with confidence analysis on market sizing, competitive intelligence, pipeline analysis, deal benchmarking, top level sales data, and company or product profiling
  • Create and edit customised reports in Excel, PowerPoint or PDF
Portfolio management, R&D competitive intelligence

Portfolio Management, R&D Competitive Intelligence

Analyse the high-level global R&D landscape by indication
  • Identify the current and future events that will affect your own products and competitors
  • Use company portfolio analysis and financial forecasts to understand the competitive positions and potential product launches
  • Evaluate competing assets using a single view of the risk and return of the R&D landscape

Evaluate's consensus forecasts are the standard at Novartis, and have been for many years, per a mandate from senior management

Anthony M, Senior Director, Competitive Intelligence & Prospection, Novartis

Evaluate is easy to use and contains information that helps Zentiva select drugs for future development, particularly the consensus forecasts

Katerina S, Information Manager, Zentiva